Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Onpattro | patisiran | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
TBC | eplontersen | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Active | |||
Nexviazyme | avalglucosidase alfa | Pompe disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Myozyme | Alglucosidase | Pompe's disease | List with clinical criteria and/or conditions | Complete | ||
Inspra | Eplerenone | Post myocardial infarction | Do not list | Complete | ||
Lotemax | Loteprednol etabonate | Post-operative inflammation following cataract surgery | Do not list | Complete | ||
Livtencity | maribavir | Post-transplant cytomegalovirus infection | Reimburse with clinical criteria and/or conditions | Complete | ||
Intrarosa | prasterone | Postmenopausal vulvovaginal atrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
Brilinta | ticagrelor | Prevention of atherothrombotic events with history of myocardial infarction | Reimburse with clinical criteria and/or conditions | Complete | ||
Emgality | galcanezumab | Prevention of migraine | Reimburse with clinical criteria and/or conditions | Complete |